Search

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

PetPro Connect: Veterinary Medicine in the Digital Age

Read more on PetPro Connect - the BI app & web portal, linking pet owners and veterinarians in a world transformed by digital health and new medicine.

Cristian Torreblanca

Cristian Torreblanca Estrada, a Corporate GFE Senior Manager Controller in Germany talks about opportunities to move between professional areas and countries

Our culture

Our culture reflects who we are and is reflected in Our FOCUS and strong belief in Diversity, Equity and Inclusion as well as Sustainable Development.

FDA Approves OFEV® (nintedanib) to Treat IPF | BI US

Read more about the FDA approval of Boehringer Ingelheim's OFEV, the first Kinase Inhibitor used to treat idiopathic pulmonary fibrosis (IPF).

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Leticia develops product medical strategies

Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.

Partnering for Innovative Pet Therapeutics

BI increases commitments to sustainable development

At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing

IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US

BI announces new data for GILOTRIF®, affirming its activity in SCC of the lung with findings presented at the IASLC 2020. View ISI, PI and Med Guide.

Adopting shelter pets: Employees make a difference at work and home

Pre-Employment

Our goal of transforming DLL3-positive carcinomas

Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

Your Milestones Drive Ours

Learn more about the experiences of living with nonsmall cell lung cancer and cholangiocarcinoma as well as caring for a loved one during a cancer journey.

Embracing Differences: Our journey to diversity, equity, and inclusion

We nurture innovative ideas

At Boehringer Ingelheim, we know to really make a difference we need to innovate. That’s why we embrace and invest in innovation every single day.

Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Corporate Social Responsibility | Boehringer Ingelheim US

Boehringer Ingelheim has a strong and longstanding commitment to improving the health of people and animals, both around the world and in local communities.

Sarcoma: An expert’s perspective

Gary Schwartz, MD, Director of the Case Comprehensive Cancer Center, Cleveland, Ohio, shares his expert perspectives on sarcoma, the importance of early detection, and his hopes for the sarcoma treatment landscape.

Deciphering Circuits in Neuroscience | Boehringer Ingelheim US

Hear from Craig Lindsley, Director of the Warren Center for Neuroscience Drug Discovery on our dedication to improving mental health.

A grandmother’s empathy offers a safe space for people with mental health conditions

Supporting the Friendship Bench to improve access to mental healthcare.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers